- DiaSorin launches LIAISON® Streptococcus pneumoniae AG Assay in CE Mark countries.
Mon Sep 09 13:25:32 -0000 2024 UTC– Diasorin (FTSE MIB: DIA) has announced the launch of its latest product, the LIAISON S.pneumoniae Antigen Immunodiagnostic Assay, now available in all countries accepting the CE Mark. This new test is designed to assist in the diagnosis of pneumococcal pneumonia, a leading cause of community-acquired pneumonia (CAP).
Acute and Chronic Cases
Streptococcus pneumoniae, the bacterium responsible for this infection, is often found in both acute and chronic cases, and is a significant cause of CAP, particularly in vulnerable populations such as the elderly and those with pre-existing health conditions. Early identification of pneumococcal pneumonia is crucial for enabling targeted antimicrobial therapy, allowing healthcare providers to reduce the use of broad-spectrum antibiotics.
First of its Kind Assay
The LIAISON.pneumoniae Ag assay is the first of its kind to offer high-throughput, qualitative detection of Streptococcus pneumoniae antigen in urine samples. The test can be completed in just 35 minutes using the LIAISON CLIA family of analyzers, providing a quick and automated solution for microbiology laboratories. This innovation includes high inclusivity, identifying 91 serotypes, and supports clinical decision-making, particularly in antibiotic stewardship.
Diasorin’s introduction of this test is expected to significantly improve the management and treatment of pneumococcal pneumonia, offering a faster, more accurate diagnosis.